gene therapy pioneer to biotech rebuff?

Gene therapy company uniQure – once a frontrunner in the field – is facing trouble, with dwindling sales and major setbacks in research and development. The Danish firm, formerly known as Amsterdam Molecular Therapeutics, has had to slash its workforce and restructure in a bid to stay afloat. Trials for a potential Huntington’s disease treatment showed mixed results, and costs for its hemophilia drug, HEMGENIX, were considered too high.